Skip to main content

Table 3 Healthcare resource utilization pre- and post-ALIS initiation (N = 331)

From: Impact of initiation of amikacin liposome inhalation suspension on hospitalizations and other healthcare resource utilization measures: a retrospective cohort study in real-world settings

 

Baseline (pre-ALIS)

Follow-up (post-ALIS initiation)

7−12 months

0−6 months (reference)

0−6 months

P value

7−12 months

P value

Hospitalizationsa

 Proportion of patients with hospitalizations, n (%)

      

  All-cause

93 (28.1)

119 (35.9)

88 (26.6)

0.0033b

76 (23.0)

 < 0.0001b

  Respiratory disease–related

67 (20.2)

89 (26.9)

64 (19.3)

0.0061b

51 (15.4)

 < 0.0001b

 Number of hospitalizations per patient per 6 months, mean ± SD

      

  All-cause

0.9 ± 1.4

1.2 ± 1.8

0.7 ± 1.2

0.0002c

0.7 ± 1.4

 < 0.0001c

  Respiratory disease–related

0.7 ± 1.2

1.0 ± 1.6

0.6 ± 1.0

0.0002c

0.6 ± 1.2

0.0001c

 LOS (per hospital admission), mean ± SD, days

      

  All-cause

4.7 ± 4.1

6.2 ± 4.9

3.9 ± 3.8

0.0004c

4.9 ± 5.6

0.0055c

  Respiratory disease–related

4.9 ± 4.1

6.2 ± 4.5

4.4 ± 4.0

0.0116c

5.2 ± 5.7

0.0209c

ED visits

 Proportion of patients with ED visits, n (%)

      

  All-cause

41 (12.4)

39 (11.8)

37 (11.2)

0.7576b

29 (8.8)

0.1573b

  Respiratory disease–related

15 (4.5)

17 (5.1)

10 (3.0)

0.0896b

18 (5.4)

0.8415b

 Number of ED visits per patient per 6 months, mean ± SD

      

  All-cause

0.6 ± 1.1

0.6 ± 1.2

0.7 ± 1.7

0.3202c

0.5 ± 1.1

0.1455c

  Respiratory disease–related

0.5 ± 1.2

0.5 ± 0.9

0.4 ± 1.3

0.3619c

0.5 ± 0.9

0.7945c

Outpatient office visits

 Proportion of patients with outpatient visits, n (%)

      

  All-cause

294 (88.8)

296 (89.4)

289 (87.3)

0.1779b

285 (86.1)

0.0934b

  Respiratory disease–related

193 (58.3)

219 (66.2)

196 (59.2)

0.0088b

179 (54.1)

 < 0.0001b

 Number of outpatient visits per patient per 6 months, mean ± SD

      

  All-cause

6.2 ± 7.5

7.3 ± 8.6

7.4 ± 13.0

0.0071c

6.8 ± 12.8

0.0028c

  Respiratory disease–related

2.4 ± 3.3

3.3 ± 5.0

3.0 ± 9.4

 < 0.0001c

2.2 ± 3.5

 < 0.0001c

  1. The outcomes before and after ALIS initiation for the same patient population were compared
  2. ALIS amikacin liposome inhalation suspension, ED emergency department, LOS length of stay, SD standard deviation
  3. aHospitalizations included inpatient stays as well as hospital ED visits that led to inpatient admission
  4. bMcNemar’s Χ2 tests were used to test statistically significant differences
  5. cWilcoxon signed rank tests were used to test statistically significant differences